Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Open access
Zhu, Hai-Dong, Li, Hai-Liang, Huang, Ming-Sheng, Yang, Wei-Zhu, Yin, Guo-Wen, Zhong, Bin-Yan, Sun, Jun-Hui, Jin, Zhi-Cheng, Chen, Jian-Jian, Ge, Nai-Jian, Ding, Wen-Bin, Li, Wen-Hui, Huang, Jin-Hua, Mu, Wei, Gu, Shan-Zhi, Li, Jia-Ping, Zhao, Hui, Wen, Shu-Wei, Lei, Yan-Ming, Song, Yu-Sheng, Yuan, Chun-Wang, Wang, Wei-Dong, Huang, Ming, Zhao, Wei, Wu, Jian-Bing, Wang, Song, Zhu, Xu, Han, Jian-Jun, Ren, Wei-Xin, Lu, Zai-Ming, Xing, Wen-Ge, Fan, Yong, Lin, Hai-Lan, Zhang, Zi-Shu, Xu, Guo-Hui, Hu, Wen-Hao, Tu, Qiang, Su, Hong-Ying, Zheng, Chuan-Sheng, Chen, Yong, Zhao, Xu-Ya, Fang, Zhu-Ting, Wang, Qi, Zhao, Jin-Wei, Xu, Ai-Bing, Xu, Jian, Wu, Qing-Hua, Niu, Huan-Zhang, Wang, Jian, Dai, Feng, Feng, Dui-Ping, Li, Qing-Dong, Shi, Rong-Shu, Li, Jia-Rui, Yang, Guang, Shi, Hai-Bin, Ji, Jian-Song, Liu, Yu-E, Cai, Zheng, Yang, Po, Zhao, Yang, Zhu, Xiao-Li, Lu, Li-Gong, Teng, Gao-Jun, for the CHANCE001 Investigators·2023·Signal Transduction and Targeted Therapy

Abstract

There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4–11.0) versus 8.0 months (95% CI, 6.6–9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1–27.3] vs. 15.7 months [13.0–20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-01235-0

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Metadata

Authors
Zhu, H.-D., Li, H.-L., Huang, M.-S., Yang, W.-Z., Yin, G.-W., Zhong, B.-Y., Sun, J.-H., Jin, Z.-C., Chen, J.-J., Ge, N.-J., Ding, W.-B., Li, W.-H., Huang, J.-H., Mu, W., Gu, S.-Z., Li, J.-P., Zhao, H., Wen, S.-W., Lei, Y.-M., Song, Y.-S., Yuan, C.-W., Wang, W.-D., Huang, M., Zhao, W., Wu, J.-B., Wang, S., Zhu, X., Han, J.-J., Ren, W.-X., Lu, Z.-M., Xing, W.-G., Fan, Y., Lin, H.-L., Zhang, Z.-S., Xu, G.-H., Hu, W.-H., Tu, Q., Su, H.-Y., Zheng, C.-S., Chen, Y., Zhao, X.-Y., Fang, Z.-T., Wang, Q., Zhao, J.-W., Xu, A.-B., Xu, J., Wu, Q.-H., Niu, H.-Z., Wang, J., Dai, F., Feng, D.-P., Li, Q.-D., Shi, R.-S., Li, J.-R., Yang, G., Shi, H.-B., Ji, J.-S., Liu, Y.-E., Cai, Z., Yang, P., Zhao, Y., Zhu, X.-L., Lu, L.-G., Teng, G.-J., & for the CHANCE001 Investigators
Venue
Signal Transduction and Targeted Therapy
Published
2023-02-08
Volume
8
Issue
1
Pages
58-58
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4319335912
Cited by
294
References
47
FWCI
41.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). https://app.cochat.ai/papers/10.1038/s41392-022-01235-0
The paper
Zhu, H.-D., Li, H.-L., Huang, M.-S., Yang, W.-Z., Yin, G.-W., Zhong, B.-Y., Sun, J.-H., Jin, Z.-C., Chen, J.-J., Ge, N.-J., Ding, W.-B., Li, W.-H., Huang, J.-H., Mu, W., Gu, S.-Z., Li, J.-P., Zhao, H., Wen, S.-W., Lei, Y.-M., . . . for the CHANCE001 Investigators. (2023). Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-01235-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.